🇺🇸 US 실적속보 by TNBfolio

Spero Therapeutics, Inc. (SPRO)
시가총액: 71.80M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://sperotherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, MoM)
2406: 10.2M / 4.9M / 108.2% / 1194.4% / 142.6%
2403: 4.2M / -- / -- / 468.1% / -94.1%
2312: 71.83M / -- / -- / -- / 207.2%
2309: 23.38M / -- / -- / -- / 2867.3%
2306: 788.0K / -- / -- / -- / 6.5%

- 분기 EPS(공시, 예측, 서프, YoY, MoM)
2406: -0.33 / -0.38 / 13.2% / -43.5% / -37.5%
2403: -0.24 / -- / -- / 4.0% / --
2312: -- / -- / -- / -- / --
2309: -0.06 / -- / -- / -- / 73.9%
2306: -0.23 / -- / -- / -- / 8.0%

- 연간 매출(YoY%), EPS(YoY%)
2312: 96.73M(99.1%) / 0.43(135.0%)
2212: 48.58M(1482.4%) / -1.23(57.7%)
2112: 3.07M(1089.9%) / -2.91(17.3%)
2012: 258000.0(--) / -3.52(--)

#SPRO

- 사업요약: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the Unite...

17 views뉴스크롤러, 20:16

#SPRO

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
https://finance.yahoo.com/news/spero-therapeutics-report-second-quarter-200500750.html

3 Micro-Cap Moonshots for Fearless Investors
https://finance.yahoo.com/news/3-micro-cap-moonshots-fearless-190722790.html

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/spero-therapeutics-announces-inducement-grant-170500838.html

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
https://finance.yahoo.com/news/denali-therapeutics-dnli-moves-5-130700445.html

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
https://finance.yahoo.com/news/spero-therapeutics-participate-h-c-200500624.html

Yahoo Finance

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial…

25 views뉴스크롤러, 20:16

🇺🇸 US 실적속보 by TNBfolio

Spero Therapeutics, Inc. (SPRO)
시가총액: 67.02M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://sperotherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2409: 13.47M / 5M / 169.4% / -42.4% / 32.1%
2406: 10.2M / 4.9M / 108.2% / 1194.4% / 142.6%
2403: 4.2M / -- / -- / 468.1% / -94.1%
2312: 71.83M / -- / -- / -- / 207.2%
2309: 23.38M / -- / -- / -- / 2867.3%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2409: -0.32 / -0.5 / 36.0% / -433.3% / 3.0%
2406: -0.33 / -0.38 / 13.2% / -43.5% / -37.5%
2403: -0.24 / -- / -- / 4.0% / --
2312: -- / -- / -- / -- / --
2309: -0.06 / -- / -- / -- / 73.9%

- 연간 매출(YoY%), EPS(YoY%)
2312: 96.73M(99.1%) / 0.43(135.0%)
2212: 48.58M(1482.4%) / -1.23(57.7%)
2112: 3.07M(1089.9%) / -2.91(17.3%)
2012: 258000.0(--) / -3.52(--)

#SPRO

- 사업요약: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare di...

35 views뉴스크롤러, 21:11

🇺🇸 US 실적속보 by TNBfolio

#SPRO

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
https://finance.yahoo.com/news/spero-therapeutics-announces-third-quarter-210500106.html

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings
https://finance.yahoo.com/news/expect-spero-therapeutics-inc-spro-122934198.html

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
https://finance.yahoo.com/news/spero-therapeutics-report-third-quarter-210500748.html

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
https://finance.yahoo.com/news/equillium-inc-eq-report-q3-150017546.html

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
https://finance.yahoo.com/news/arbutus-biopharma-abus-reports-q3-134507550.html

Yahoo Finance

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO)…

38 views뉴스크롤러, 21:11

🇺🇸 US 실적속보 by TNBfolio

11월 15일 ~17일 외사 기업 리포트

등급 상향
#MA, #RGNX, #SPRO, #AMAT, #ELUT, #ASND, #CDXS, #ANNX, #TSLA, #NVDA, #MT, #DIS, #MRK, #BILI, #DAL, #TPR, #CRM, #GLOB, #ALLY, #MDXG

등급 하향
#INVZ, #CYBN, #CPT, #BLUE, #AMX, #GIS, #CMTG, #HPP, #MDT

https://naver.me/GCvTu2QW

Naver

11월 15일~17일 외사 기업 TP정리

11월 15일~17일 외사 기업 TP정리 가) 등급 상향 1. Mastercard (#MA) - 기업 개요: 신용카드 및 결제 네트워크 서비스를 제공하며 글로벌 결제 시장을 선도하는 기업 - 금융회사: Piper Sandler - 등급 변

490 views14:50

🇺🇸 US 실적속보 by TNBfolio

241118 US 기업 TP 정리

가) 등급 상향

#BFAM #CNCOR #CVS #HPE #PFGC #BAM #PANW #DIS #BE #GILD #PANW #PANW #ADSK #CMA #GLBE #AMLX #APD #AUTL #CBRL #FUTU #HOOD #MBI #MPWR #MRNA #PRMB #ROKU #UFCS

나) 등급 하향

#ANTX #BIIB #CAR #CR #CRL #CW #EOG #ESAB #EYEN #EYEN #FBK #FTV #IR #LBTYA #MATX #NBHC #PH #PNFP #PNW #RDFN #SPRO #PLUG #MRNA #NKE

https://naver.me/xOxwkJba

Naver

11월 18 외사 기업 TP정리

228 views14:37

🇺🇸 US 실적속보 by TNBfolio

Spero Therapeutics, Inc. (SPRO)
시가총액: 46.89M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://sperotherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2412: 15.04M / 4.5M / 234.2% / -79.1% / 11.7%
2409: 13.47M / 5M / 169.4% / -42.4% / 32.1%
2406: 10.2M / 4.9M / 108.2% / 1194.4% / 142.6%
2403: 4.2M / -- / -- / 468.1% / -94.1%
2312: 71.83M / -- / -- / -- / 207.2%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2412: -0.38 / -0.36 / -5.6% / -- / -18.8%
2409: -0.32 / -0.5 / 36.0% / -433.3% / 3.0%
2406: -0.33 / -0.38 / 13.2% / -43.5% / -37.5%
2403: -0.24 / -- / -- / 4.0% / --
2312: -- / -- / -- / -- / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 96.73M(99.1%) / 0.43(135.0%)
2212: 48.58M(1482.4%) / -1.23(57.7%)
2112: 3.07M(1089.9%) / -2.91(17.3%)
2012: 258000.0(--) / -3.52(--)

#SPRO

- 사업요약: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infecti...

64 views20:05

🇺🇸 US 실적속보 by TNBfolio

Spero Therapeutics, Inc. (SPRO)
시가총액: 38.57M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://sperotherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 5.87M / 11M / -46.6% / 39.6% / -61.0%
2412: 15.04M / 4.5M / 234.2% / -79.1% / 11.7%
2409: 13.47M / 5M / 169.4% / -42.4% / 32.1%
2406: 10.2M / 4.9M / 108.2% / 1194.4% / 142.6%
2403: 4.2M / -- / -- / 468.1% / -94.1%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.25 / -0.27 / 7.4% / -4.2% / 34.2%
2412: -0.38 / -0.36 / -5.6% / -- / -18.8%
2409: -0.32 / -0.5 / 36.0% / -433.3% / 3.0%
2406: -0.33 / -0.38 / 13.2% / -43.5% / -37.5%
2403: -0.24 / -- / -- / 4.0% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 96.73M(99.1%) / 0.43(135.0%)
2212: 48.58M(1482.4%) / -1.23(57.7%)
2112: 3.07M(1089.9%) / -2.91(17.3%)
2012: 258000.0(--) / -3.52(--)

#SPRO

- 사업요약: Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (M...

51 views20:05

About

Blog

Apps

Platform